NCT03392701 is a NA clinical trial of LPS infusion in Sepsis, sponsored by Barmherzige Brüder Linz.

Who is sponsoring NCT03392701?

NCT03392701 is sponsored by Barmherzige Brüder Linz.

What drugs are being tested in NCT03392701?

Interventions in NCT03392701: LPS infusion.

What condition does NCT03392701 study?

NCT03392701 studies Sepsis, Inflammation, LPS, Lipid Metabolism Disorder.

Is NCT03392701 still recruiting?

NCT03392701 is currently completed. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT03392701

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Possible Links Between Inflammation and Lipid Metabolism

Completed NA Last updated 17 October 2018

What this trial tests

NA trial testing LPS infusion in Sepsis in 10 participants. Completed in 30 September 2018.

Timeline

20 December 2017

Primary endpoint
30 July 2018

30 September 2018

Quick facts

Lead sponsor	Barmherzige Brüder Linz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	10
Start date	20 December 2017
Primary completion	30 July 2018
Estimated completion	30 September 2018
Sites	1 location across Austria

Drugs / interventions tested

LPS infusion — full drug profile →

Conditions studied

Sepsis — all drugs for Sepsis →
Inflammation — all drugs for Inflammation →
LPS — all drugs for LPS →
Lipid Metabolism Disorder — all drugs for Lipid Metabolism Disorder →

Sponsor

Barmherzige Brüder Linz

Who can join

Adults 18 to 40, male only, with Sepsis or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It has been recognized lately that sepsis and inflammation has an important impact on lipid metabolism and that the extent of hypocholesterolemia may even be a marker of severity of illness. However, the interplay between inflammation and the marked changes in lipid metabolism remain to be sufficiently understood. Importantly, the exact kinetics of lipid parameters in inflammatory conditions are yet to be explored. This study aims to investigate the interaction between inflammation and lipid metabolism using the human endotoxin model (LPS infusion) in ten healthy volunteers in a single blinded randomized placebo controlled cross-over design.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.
Millischer V, Heinzl M, Faka A, Resl M, et al · · 2021 · cited 24× · PMID 34273987 · DOI 10.1186/s12974-021-02196-x
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Not Induced in Artificial Human Inflammation and Is Not Correlated with Inflammatory Response.
Heinzl MW, Resl M, Klammer C, Egger M, et al · · 2020 · cited 13× · PMID 31843964 · DOI 10.1128/iai.00842-19
SUBCLINICAL KIDNEY INJURY IS CAUSED BY A MODERATE SINGLE INFLAMMATORY EVENT.
Heinzl MW, Resl M, Klammer C, Fellinger P, et al · · 2022 · cited 3× · PMID 35616594 · DOI 10.1097/shk.0000000000001942

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03392701 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Barmherzige Brüder Linz
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03392701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing